Kenvue's Tylenol With Naproxen Combination Tablet Gets FDA Approval for Pain Relief

MT Newswires Live07-24

Kenvue's (KVUE) Kenvue Brands unit received approval for its Tylenol with Naproxen combination tablet to provide up to 12 hours of pain relief in adults and children 12 years and older, the US Food and Drug Administration said Friday.

The nonprescription combination product is indicated for temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor arthritis pain, the FDA said.

The agency said the approval was supported by data showing the effectiveness and safety of the combination drug.

Kenvue shares were up about 1.1% in Friday trading.

Price: 19.11, Change: +0.21, Percent Change: +1.08

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653403308?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653403308","market":"sg","top_or_hot":-1,"title":"Kenvue's Tylenol With Naproxen Combination Tablet Gets FDA Approval for Pain Relief","media":"MT Newswires Live","content":"<html><body><p> Kenvue's (KVUE) Kenvue Brands unit received approval for its Tylenol with Naproxen combination tablet to provide up to 12 hours of pain relief in adults and children 12 years and older, the US Food and Drug Administration said Friday.</p><p>The nonprescription combination product is indicated for temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor arthritis pain, the FDA said.</p><p>The agency said the approval was supported by data showing the effectiveness and safety of the combination drug.</p><p>Kenvue shares were up about 1.1% in Friday trading.</p><p>Price: 19.11, Change: +0.21, Percent Change: +1.08</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kenvue's Tylenol With Naproxen Combination Tablet Gets FDA Approval for Pain Relief</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKenvue's Tylenol With Naproxen Combination Tablet Gets FDA Approval for Pain Relief\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-24 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Kenvue's (KVUE) Kenvue Brands unit received approval for its Tylenol with Naproxen combination tablet to provide up to 12 hours of pain relief in adults and children 12 years and older, the US Food and Drug Administration said Friday.</p><p>The nonprescription combination product is indicated for temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor arthritis pain, the FDA said.</p><p>The agency said the approval was supported by data showing the effectiveness and safety of the combination drug.</p><p>Kenvue shares were up about 1.1% in Friday trading.</p><p>Price: 19.11, Change: +0.21, Percent Change: +1.08</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653403308","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653403308","pubTimestamp":1784905052,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kenvue's  Kenvue Brands unit received approval for its Tylenol with Naproxen combination tablet to provide up to 12 hours of pain relief in adults and children 12 years and older, the US Food and Drug Administration said Friday.The nonprescription combination product is indicated for temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor arthritis pain, the FDA said.The agency said the approval was supported by data showing the effectiveness and safety of the combination drug.Kenvue shares were up about 1.1% in Friday trading.Price: 19.11, Change: +0.21, Percent Change: +1.08","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","RSPS":"Invesco S&P 500 Equal Weight Consumer Staples ETF","BK4588":"碎股","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","KVUE":"Kenvue Inc","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LABU":"三倍做多标普生物-Direxion","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC"},"translate_title":"Kenvue 的泰诺与萘普生复方片获得 FDA 批准用于缓解疼痛","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLAM":0.6,"KVUE":1,"RSPS":0.6,"LABU":1.5},"content_text":"Kenvue's (KVUE) Kenvue Brands unit received approval for its Tylenol with Naproxen combination tablet to provide up to 12 hours of pain relief in adults and children 12 years and older, the US Food and Drug Administration said Friday.The nonprescription combination product is indicated for temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor arthritis pain, the FDA said.The agency said the approval was supported by data showing the effectiveness and safety of the combination drug.Kenvue shares were up about 1.1% in Friday trading.Price: 19.11, Change: +0.21, Percent Change: +1.08","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653403308","isCrawlerRequest":true}